Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 8/20 | 0.45 |
| ▸ | DRD4 | P21917 | 7/20 | 0.45 |
| ▸ | DRD3 | P35462 | 7/20 | 0.45 |
| ▸ | DRD1 | P21728 | 4/20 | 0.45 |
| ▸ | DRD5 | P21918 | 4/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9325324 | 0.80 | MTNR1A (0.56) | DRD2DRD1MTNR1ASLC6A4 | |
| SCHEMBL6307480 | 0.79 | HTR1A (0.62) | HTR6DRD2DRD4DRD3CHRM1 | |
| SCHEMBL28504373 | 0.78 | HTR6 (0.44) | HTR6DRD2DRD4DRD3DRD1 | |
| SCHEMBL21590355 | 0.77 | DRD2 (0.64) | HTR6DRD2DRD4DRD3DRD1 | |
| SCHEMBL1248524 | 0.75 | SLC6A4 (0.45) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL21590356 | 0.75 | DRD3 (0.62) | HTR6DRD2DRD4DRD3DRD1 | |
| SCHEMBL4542485 | 0.75 | HTR1A (0.45) | HTR6DRD2DRD4DRD3DRD1 | |
| SCHEMBL1387940 | 0.74 | HTR6 (0.46) | HTR6DRD2MTNR1ASLC6A4HTR2A | |
| SCHEMBL6313386 | 0.74 | MTNR1A (0.46) | HTR6DRD2MTNR1ASLC6A4 | |
| SCHEMBL8185072 | 0.73 | DRD2 (0.50) | HTR6DRD2SLC6A4HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080090-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2005-04-14 | — | — | US | disclosed |
| US-20020058811-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0767782-B1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-10-31 | — | — | EP | disclosed |
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | CHENARD BERTRAND L (US) | 2001-06-21 | — | — | US | disclosed |
| EP-0689536-B1 | NAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6166020-A | Aryl and heteroaryl alkoxynaphthalene derivatives | PFIZER INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0701819-B1 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5821245-A | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0795328-A1 | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0767782-A1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1996000720-A1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0689536-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010004669-A1 | Pyrazinyl-substituted naphthalene derivatives | HTR4, HCRTR2, CNR2 | HTR6 26/4885DRD2 144/4885DRD4 168/4885 |
| US-20050080090-A1 | Naphthalene derivatives | HTR4, NPY4R, HCRTR1 | HTR6 54/4885DRD2 92/4885DRD4 77/4885 |
| US-20020058811-A1 | Naphthalene derivatives | HTR4, CNR1, CNR2 | HTR6 25/4885DRD2 121/4885DRD4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.